The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: A belgian multicentre prospective phase II clinical study

Annals of Surgical Oncology

Volumn 19, Issue 7, 2012, Pages 2186-2194

  Hompes, Daphne ^a   D'Hoore, André ^a   Van Cutsem, Eric ^a   Fieuws, Steffen ^b   Ceelen, Wim ^c   Peeters, Marc ^c   Van Der Speeten, Kurt ^d   Bertrand, Claude ^e   Legendre, Hugues ^f   Kerger, Joseph ^f  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b KU LEUVEN   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d DEPARTMENT OF CARDIOLOGY   (Belgium)

^e Hospital de Jolimont   (Belgium)

^f UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ABDOMINAL ABSCESS; ADJUVANT THERAPY; ADULT; AGED; ANASTOMOSIS LEAKAGE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGISTRY; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEART DISEASE; HEMATOLOGIC DISEASE; HOSPITALIZATION; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; ILEUS; INTESTINE PERFORATION; LUNG DISEASE; MALE; MORBIDITY; MULTICENTER STUDY; OPERATION DURATION; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE HEMORRHAGE; PROSPECTIVE STUDY; RECTOVAGINAL FISTULA; REVIEW; URINARY TRACT DISEASE;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84865153844     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2264-z     Document Type: Review

References (45)

1. Verwaal VJ, Zoetmulder FAN, et al. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2005;12:65-71. (Pubitemid 40486643)
2. Cararo P, Segala M, Cesana D, et al. Obstructing colonic cancer: failure and survival patterns over ten-year follow-up after one-stage curative surgery. Dis Colon Rectum. 2001;44:243-50. (Pubitemid 32173774)
3. Jayne D, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545-50. (Pubitemid 35404323)
4. Russell A, Pelton J, Reheis C, et al. Adenocarcinoma of the colon: an autopsy study with implications for new therapeutic strategies. Cancer. 1985;56:1446-51. (Pubitemid 15230595)
5. Koppe MJ, Bleichrodt RP, et al. Peritoneal carcinomatosis of colorectal origin: incidence and treatment strategies. Ann Surg. 2006;243:212-22. (Pubitemid 43185440)
6. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecological malignancies: results from the EVO-CAPE 1 multicentric prospective study. Cancer. 2000;88:358-63. (Pubitemid 30051820)
7. Shen P, Levine E, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcino-matosis. Arch Surg. 2003;138:26-33. (Pubitemid 36055643)
8. Sugarbaker PH, et al. Management of peritoneal-surface malignancy: the surgeon's role. Langenbecks Arch Surg. 1999;384: 576-87. (Pubitemid 30020346)
9. Ragnhammar P, Hafstrom L, et al.; SBU-Group. Swedish Council of Technology assessment in health care. A systematic overview of chemotherapy effects in colorectal cancer. Acta Oncol. 2001;40:282-308.
10. Pestieau SR, Sugarbaker PH, et al. Pharmacokinetics of intra-peritoneal oxaliplatin: experimental studies. J Surg Oncol. 2001;76:106-14.
11. Mahteme H, Pahlman L, et al. Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion. Eur J Clin Pharmacol. 2008;64:907-11.
12. Elias D, Bonnay M, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13: 267-72. (Pubitemid 34704979)
13. Jacquet P, Sugarbaker PH, et al. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinoma-tosis. In: Sugarbaker PH, editor. Peritoneal carcinomatosis: principles of management. Boston: Kluwer Academic; 1996. p 359-37.
14. Sugarbaker PH, et al. Peritonectomy procedures. Surg Oncol Clin N Am. 2003;12:703-27. (Pubitemid 36920094)
15. Harrell F, et al. Regression modeling strategies. New York: Springer; 2001.
16. Heinze G, Gnant M, Schemper M, et al. Exact logrank test for unequal follow-up. Biometrics. 2003;59:1151-7. (Pubitemid 38021246)
17. Elias D, Blot F, et al. Curative treatment of peritoneal Carcino-matosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92:71-6. (Pubitemid 32623042)
18. van Leeuwen B, Graf W, Pahlman L, et al. Swedish experience with peritonectomy and HIPEC. HIPEC in peritoneal carcino-matosis. Ann Surg Oncol. 2007;15:745-53.
19. Elias D, Glehen O, Pocard M, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel and nonpseudomyxoma appendix. Ann Surg. 2010;251: 896-901.
20. Elias D, Gilly F, Boutitie F, et al. Peritoneal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63-8.
21. Glehen O, Elias D, Deraco M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multiinstitutional study. J Clin Oncol. 2004;22:3284-92. (Pubitemid 41103684)
22. Elias D, Lefevre J, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681-5.
23. Elias D, Pocard M, et al. Treatment and prevention of peritoneal carcinomatosis from colorectal cancer. Surg Oncol Clin N Am. 2003;12:543-59. (Pubitemid 36920085)
24. Cao C, Yan T, Black D, et al. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperito-neal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2009;16:2152-65.
25. Elias D, Pocard M, Goere D, et al. HIPEC with oxaliplatin in the treatment of peritoneal carcinomatosis of colorectal origin. Cancer Treat Res. 2007;134:303-18.
26. Andres A, Majno P, Morel P, et al. Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score. Ann Surg Oncol. 2008;15:134-43.
27. Arru M, Aldrighetti L, Castoldi R, et al. Analysis of prognostic factors influencing long-term survival after hepatic resection for metastatic colorectal cancer. World J Surg. 2008;32:93-103. (Pubitemid 50004245)
28. Choti M, Sitzmann J, Tiburi M, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759-66. (Pubitemid 34547293)
29. Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg. 2007;246:183-91. (Pubitemid 47196514)
30. House M, Ito H, Fong Y, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1, 600 patients during two decades at a single institution. J Am Coll Surg. 2010;210:744-52.
31. Maggiori L, Elias D, et al. Curative treatment of colorectal peritoneal carcinomatosis: current status and future trends. Eur J Surg Oncol. 2010;36:599-603.
32. Kusamura S, Elias D, Baratti D, et al. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2008;98:247-52.
33. Verwaal V, van Ruth S, De Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737-47.
34. Verwaal V, Bruijn S, Boot H, et al. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426-32.
35. Franko J, Ibrahim Z, Gusani N, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756-62.
36. Hompes D, Boot H, van Tinteren H, et al. Unresectable peritoneal carcinomatosis from colorectal cancer: a single center experience. J Surg Oncol. 2011;104:269-73.
37. van Ruth S, Mathôt R, Sapridans R, et al. Population pharma-cokinetics and pharmacodynamics of mitomycin C during intraoperative hyperthermic intraperitoneal chemotherapy. Clin Pharmacokinet. 2004;43:131-43. (Pubitemid 38283135)
38. van Ruth S, Verwaal V, Zoetmulder F, et al. Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol Clin N Am. 2003;12: 771-80. (Pubitemid 36920098)
39. Lambert L, Armstrong T, Mansfield F, et al. Incidence, risk factors and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. Ann Surg Oncol. 2009;16:2181-7.
40. Verwaal VJ, van Tinteren H, Ruth SV, et al. Toxicity of cyto-reductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol. 2004;85:61-7. (Pubitemid 38160772)
41. Graham M, Lockwood G, Greenslade D. Clinical pharmacoki-netics of oxaliplatin: a critical review. Clin Cancer Res. 2000; 6:1205-18. (Pubitemid 30226200)
42. Soulié P, Raymond E, Brienza S, et al. Oxaliplatin: the first DACH platinum in clinical practice. Bull Cancer. 1997;84: 665-73. (Pubitemid 27351535)
43. de Gramont A, Figer A, Seymour M. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-47. (Pubitemid 30644117)
44. Makatsoris T, Kalafonos HP, Aravantinos G. A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer. Int J Gastrointest Cancer. 2005; 35:103-9. (Pubitemid 41272207)
45. Scheithauer W, Kornek G, Raderer M. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2003;21:1307-12. (Pubitemid 46606408)